Enterprise Value
18.47M
Cash
4.331M
Avg Qtr Burn
-5.372M
Short % of Float
0.89%
Insider Ownership
0.60%
Institutional Own.
37.07%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ELX-02 Details Rare genetic disease, Alport Syndrome | Phase 3 Initiation | |
ELX-02 Details Cystic fibrosis, Lung disease, Glabellar lines | Phase 2 Update | |
ZKN-013 Details Rare genetic disease, Junctional epidermolysis bullosa, Recessive dystrophic epidermolysis bullosa | Phase 1 Initiation | |
ELX-02 Details Rare genetic disease | Failed Discontinued |